Danish pharmaceutical company Veloxis Pharmaceuticals A/S, has increased its capital by 1,500,000 new shares.
The company said on Monday that new nominal value of DKK 0.10 each corresponds to nominal DKK 150,000 ($21.084/€20175) as a consequence of the exercise of warrants by former employees of the company granted under the its warrant program.
On November 11, the Veloxis’s Board has established a new warrant programme for board members and its employees.
As a result of the employee’s investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 525,000 ($73796/€70614).
The subscription prices for the new shares is DKK 0.35 per share of nominal DKK 0.10.
The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 170,337,388.10 ($24M/€23) divided into shares of DKK 0.10 each, Veloxis has said.
Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.
The last stock price was 1.08.